Vernal Biosciences Showcases Cutting-Edge Innovations at the 11th International mRNA Health Conference in Berlin

BERLIN, Germany--(BUSINESS WIRE)--Vernal Biosciences, a leading Contract Development and Manufacturing Organization (CDMO) specializing in mRNA and LNP manufacturing, proudly announces its participation in the 11th International mRNA Health Conference held in Berlin. At the conference, Vernal Biosciences will unveil three groundbreaking posters that highlight innovative advancements in mRNA technologies and the flexibility of Vernal’s platform process technologies.

mRNA Capping Technologies: Effects on Quality Attributes, Biological Effects, and Innate Immune Stimulation

Vernal Biosciences compares the effects of two important mRNA capping technologies, an enzymatic capping process and a co-transcriptional capping process, on quality attributes Cap 1 content, double-stranded RNA (dsRNA) content, mRNA integrity, in vivo potency, and innate immune stimulation. Additionally, this poster showcases the benefits of Vernal’s optimized, proprietary process on mRNA purity. This comprehensive research presents new insights into optimizing mRNA production, offering a deeper understanding of the intricate relationships between capping and mRNA quality.

Evaluation of Doggybone DNA as a Template for In Vitro Transcription

The second poster explores the utility of doggybone DNA (dbDNA) as a template for in vitro transcription, revealing a novel and promising approach to mRNA synthesis. Vernal Biosciences' research highlights the advantages of dbDNA, a novel IVT template type from Touchlight, in enhancing the quality attributes and biological potency of mRNA production.

Novel Plasmid DNA-Encoded Poly(A) Tails for mRNA Synthesis

In the third poster, Vernal Biosciences introduces groundbreaking research on novel plasmid DNA-encoded poly(A) tails for mRNA synthesis. This innovative approach improves template stability, and when used with Vernal’s proprietary process conditions, results in enhanced mRNA integrity, reduction in dsRNA content, and improved in vivo potency versus an mRNA containing a poly(A) 120 tail.

Dr. Christian Cobaugh, Chief Executive Officer at Vernal Biosciences, stated, "We are excited to share these groundbreaking findings at the 11th International mRNA Health Conference. Vernal Biosciences is dedicated to pushing the boundaries of mRNA technology, and these posters reflect our commitment to manufacturing high purity mRNA and advancing the field for the benefit of patients and the broader scientific community."

The 11th International mRNA Health Conference is a premier platform for industry leaders and researchers to exchange ideas and drive innovations in mRNA therapeutics. Vernal Biosciences' participation in the event underlines the company's commitment to staying at the forefront of the industry.

About Vernal Biosciences:

Vernal Biosciences is a leading Contract Development and Manufacturing Organization (CDMO) specializing in mRNA and LNP manufacturing. We provide comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Our dedicated team of experts, platform solutions, and GMP facility shows our commitment to our partners, enabling them to focus on accelerating their programs into clinical development to improve patient lives.

For more information about Vernal Biosciences and its pioneering work in mRNA technologies, please visit www.vernal.bio.